NHS England advising physicians on biosimilars

Knowing when to prescribe biosimilars is a massive issue internationally, and action is being taken on the issue in the UK to make sure they are used appropriately and in consultation with patients.

NHS England has engaged with local stakeholders with decision-making responsibility for commissioning, prescribing, dispensing and monitoring biological medicines, as well as patient representatives.

This approach has been supported by partners including the Association of the British Pharmaceutical Industry (ABPI), the trade group representing UK pharma, and the need for it was shown by a recent poll showing that less than half of global doctors currently feel confident handing out biosimilars to patients.